Your session is about to expire
← Back to Search
Janus Kinase (JAK) Inhibitor
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
Phase 2
Waitlist Available
Led By Brett King, MD, PhD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group
Summary
The purpose of the study is to investigate the use of topical tofacitinib to promote hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis.
Eligible Conditions
- Alopecia Areata
- Alopecia Universalis
- Alopecia Totalis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Percent Change in Severity of Alopecia Tool (SALT) Score
Secondary study objectives
Treatment Response Assessed as the Number of Participants With Hair Regrowth
Side effects data
From 2018 Phase 2 trial • 10 Patients • NCT0281234240%
Upper Respiratory Infection
40%
Scalp Skin Irritation
20%
Headache
10%
Sinus Infection
10%
Folliculitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tofacitinib Ointment
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Tofacitinib ointmentExperimental Treatment1 Intervention
Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tofacitinib
FDA approved
Find a Location
Who is running the clinical trial?
Yale UniversityLead Sponsor
1,930 Previous Clinical Trials
3,033,464 Total Patients Enrolled
5 Trials studying Alopecia Areata
69 Patients Enrolled for Alopecia Areata
Brett King, MD, PhDPrincipal InvestigatorYale University
4 Previous Clinical Trials
19 Total Patients Enrolled
3 Trials studying Alopecia Areata
19 Patients Enrolled for Alopecia Areata